anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This medication is to be used as directed by a physician and should not be used to treat any condition other than that for which it was prescribed. If redness or irritation occurs, discontinue use and consult a physician.

PREGNANCY: Pregnancy Category B. Animal reproduction studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. Because animal reproductive studies are not always predictive of human response, Urea 40% should be given to a pregnant woman only if clearly needed.

NURSING MOTHERS: It is not known whether or not this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Urea 40% is administered to a nursing woman.
The present invention relates to a method of medical monitoring, a medical monitoring system and a computer program to control a medical monitoring system. In order to provide an improved monitoring technique that allows a more effective recognition of monitored data a method of medical monitoring is suggested, the method using data collected by a number of sensors (2), the sensors (2) are positioned on a patient in a way that the sensors (2) form a predefined arrangement and the collected data depend on the position of the sensor (2) on the patient. According to the invention the method comprises the step of displaying data using a number of multiaxis diagrams (6, 7) in which the position of the axes (8, 10) is related to the position of the sensors (2) in the predefined arrangement, and on each axis (8, 10) data from its related sensor (2) is displayed. Whereas known monitoring techniques merely display medical data on axes which are defined in a more or less arbitrary way, the present invention suggests to use a multiaxis diagram (6, 7) in a way, that each axis (8, 10) represents one particular dimension of data. In other words not only the pure values, but additional spatial information (12, 13, 18) are displayed and provided to a user, e. g. to a physician. With this addition-al information a two- or even three-dimensional representation of data and therefore a localization of data is provided. The monitoring technique according to the invention thus allows a more effective recognition of monitored data. Physicians are enabled to carry out a fast pattern recognition in order to recognize and to evaluate the situation of the patient in a quicker and more effective way.
Overweight and obese children and adolescents at risk for non alcoholic fatty liver disease will undergo oral glucose tolerance testing (ogtt), genotyping, abdominal and liver magnetic resonance imaging (mri), and will provide a stool sample at baseline and at 2 year follow up. A small subset will undergo liver biopsy to test for hepatic steatosis and nonalcoholic steatohepatitis.
BACKGROUND: Cytomegalovirus (CMV) mismatched, donor IgG-positive/recipient IgG-negative, solid organ transplant recipients (SOTRs) are at high risk of CMV invasive disease. Post-prophylaxis disease is an issue in this population. Some programs employ surveillance after prophylaxis (SAP) to limit the incidence of post-prophylaxis disease.
METHODS: This was a single-center retrospective cohort study that included all CMV mismatched SOTRs from 2003 to 2017. Patients underwent SAP with weekly CMV plasma viral load for 12 weeks. The subjects were classified into three post-prophylaxis DNAemia patterns: no DNAemia, one episode of DNAemia, and multiple episodes of DNAemia. We calculated the cumulative incidence of each DNAemia pattern. We also determined 5-year mortality based on DNAemia pattern stratified by organ transplant type.
RESULTS: Post-prophylaxis recurrent DNAemia occurred in 63% of lung recipients and 32% of non-lung recipients (p =  .003). Tissue invasive CMV disease was diagnosed in 3% of the population and CMV syndrome was diagnosed in 33%. Recurrent DNAemia was not associated with 5-year mortality.
CONCLUSION: In this cohort, undergoing SAP tissue invasive disease was uncommon and CMV DNAemia recurrence did not have an impact on long-term mortality.
PURPOSE:To provide a toothpaste composition causing no drop of viscosity despite change in temperature or ionic concentrations, maintaining favorable tube extrudability and shape retainability, excellent in mouth feeding and rinsability, formulated with an aqueous suspension of a pulverized cellulosic material. CONSTITUTION:This toothpaste composition is formulated with 0.2-10wt.% of an aqueous suspension of a pulverized cellulosic material having 0.3-6mum particle size corresponding to 50% of cumulative volume and with the cumulative volume for the particles having <=3mum particle size accounting for >=25% of the whole volume. The concentration of the cellulosic material in the suspension is pref. 2-25wt.%. This level of concentration facilitates the handing. The size of particles corresponding to 50% of cumulative volume means the sphere- equivalent diameter for the particles whose cumulative volume accounts for 50% of the whole particles' volume. Said suspension preserves highly smooth creaminess and shape retainability in a stably dispersed state.
Active treatment will be irradiated using a Multi Radiance Medical Super Pulsed Laser, manufactured by Multi Radiance Medical® (Solon,Ohio, USA), at 5 sites in the knee area, with a dose of 8.02 J per site. The treatment will be performed 3 times a week, for four consecutive weeks, yielding 12 treatments.
Sustained delivery compositions which modulate the release of incorporated prophylactic, therapeutic, and/or diagnostic agents, and methods of preparation and use thereof, are disclosed. The compositions include a biocompatible polymeric matrix; a prophylactic, therapeutic, and/or diagnostic agent dispersed within the polymeric matrix; and a monovalent cation component which is separately dispersed within the polymeric matrix. The monovalent cation component modulates the release of the incorporated agent from the polymeric matrix. The compositions can be prepared by dissolving a biocompatible polymer in a solvent to form a polymer solution, and separately dispersing a monovalent cation and a prophylactic, therapeutic, and/or diagnostic agent within the polymer solution. The polymer solution is then solidified to form a polymeric matrix, wherein a significant amount of the monovalent cations is dispersed in the polymeric matrix separately from the incorporated agent. The cation modulates the release of the incorporated agent from the polymeric matrix.
The purpose of this pilot, 12 week, clinical research study is to determine if supplementation with Vitamin D will improve the clinical outcome in subjects with chronic urticaria and angioedema (CUA). Vitamin D is a key element in the regulation of immune system responses, and vitamin D could play an important role in the treatment of CUA. Recently, we published that there is an important association with CUA and serum 25-hydroxy vitamin D (25OHD). Namely, vitamin D levels in subjects with CUA were significantly lower as compared to subjects with an alternative allergic disorder, allergic rhinitis. There is now one other observational report that supplementation with vitamin D (50,000/wk) in subjects CUA resulted in clinical improvement; however, there was only one treatment arm and optimal serum 25OHD required to obtain benefit was not investigated.

This current study is a double-blinded, prospective, interventional study that seeks to recruit adult subjects with physician-diagnosed CUA and randomize subjects to either the recommended dietary allowance (Vitamin D 600 IU/day) or the recommended upper limit of intake (Vitamin D 4000 IU/day). Subjects will answer a questionnaire to collect information regarding demographics, previous diagnostic tests, medications, and complete an urticaria severity score (USS). Information from the medical record: weight, height, body mass index (BMI), thyroid stimulating hormone (TSH), free thyroxine (T4), thyroid autoantibodies, urticaria autoimmune testing (CD203c results), anti-nuclear antibody (ANA), urinalysis, and allergy skin prick testing, which are part of the CUA evaluation will be obtained. Subjects will have research blood draws for serum 25OHD level, iPTH, calcium, phosphorus, albumin, urine calcium, and vitamin D receptor (VDR) gene expression. All subjects will receive standard-of-care therapy according to the 2009 Third International Consensus Meeting on Urticaria position guidelines. Follow-up visits for medication usage, urticaria severity score, and serum and urine safety monitoring will be at 6 and 12 weeks.

The hypothesis of this study is that high dosing of vitamin D will result in clinical improvement in subjects with CUA. The primary clinical endpoint is medication usage, and the secondary outcomes are urticaria severity score and prednisone rescue use. We will explore if threshold serum 25OHD levels correlate and VDR expression correlate to clinical outcomes, and to determine power analysis to conduct a larger scale study. Finally, the study aims to determine if vitamin D supplementation is safe and well-tolerated in subjects with CUA.
This study will evaluate two alternative methods of inducting syringe exchange referrals into routine methadone treatment. The sample (N=390) will be opioid-dependent injection drug users referred by the Baltimore Needle Exchange Program (BNEP) for routine outpatient methadone treatment using a stepped care model. Subjects will be randomly assigned to one of three 3-month treatment induction conditions: 1) Low Threshold Stepped Care induction (LTSC), 2) Voucher-Based Stepped Care induction (VBSC), or 3) Routine Stepped-Care induction (RSC). The LTSC condition will noticeably reduce treatment demands on new admissions during the 90-day induction period and is conceptually related to an interim maintenance schedule. It is expected to increase patient recognition of the reinforcing effects and benefits of methadone, improve the transition to more comprehensive schedules of care, and increase early retention. The VBSC condition adds an attendance reinforcement intervention to the routine stepped care induction schedule over the first 90-days of treatment. It is expected to improve early treatment engagement and retention. Subjects in each of these conditions will transition to routine stepped-care (no voucher-based reinforcement) following the 90-day induction period. The RSC condition will serve as a comparison group and represents routine care in the program where the study will be conducted. All subjects will be followed for 6-months. Retention, drug use (via urinalysis and self-report), and other infectious disease risk behaviors (e.g., syringe sharing; number of injections) are the primary outcome measures. The proposed design will also test mediational models to evaluate changes in objective indices of engagement (methadone and counseling adherence) and psychological constructs (treatment readiness and satisfaction) as predictors of outcome. Regression models will be used to evaluate the amount of reduction of drug use necessary to effect varying amounts of change in HIV risk behavior. Finally, data will be collected and compared on the treatment costs of each induction strategy.
FIELD: personal demand items. ^ SUBSTANCE: this invention discloses composition, which, in process of application on teeth, demonstrates effect of teeth whitening. Teeth whitener contains glycerol monooleate, polyol, polymer, peroxide and hydrophile dissolvent in certain quantitative ratios and is in phase of emulsion of water/oil type. Whitener may also contain peroxide stabiliser. Teeth whitener is liquid prior to application on teeth and paste-like in process of application on teeth. Besides teeth whitener thickens under effect of moisture, such as saliva, after application on teeth and, accordingly, may stick and fix to teeth. ^ EFFECT: besides changes in teeth whitener viscosity in case of temperature variation may be minimised, and rate of whitening component release may be controlled by addition of polyol. ^ 11 cl, 5 tbl, 6 ex
FIELD: medicine; veterinary medicine; immunology; virology.SUBSTANCE: group of inventions relates to the field of medicine, namely to veterinary medicine, immunology and virology; it is intended for vaccinating pigs against a disease associated with an infection of porcine circovirus type 2 (hereinafter – PCV2) and porcine reproductive and respiratory syndrome virus (hereinafter – PRRSV). A combined vaccine contains an antigen from PCV2 unable to reproduce and live PRRSV. The vaccine is an oil-in-water emulsion containing squalene and vitamin E acetate. Methods for producing the specified combined vaccine are also presented. In another embodiment, an oil-in-water emulsion is presented containing squalene and vitamin E acetate, an antigen from PCV2 unable to reproduce and live PRRSV. In one more embodiment, the use of an antigen from PCV2 unable to reproduce and live PRRSV for the production of the combined vaccine is presented. In addition, a method for vaccinating pigs against PCV2 and PRRSV by injecting the specified combined vaccine is presented.EFFECT: use of the group of inventions allows combining live PRRSV virus with inactivated antigen from PCV2, providing safe and effective vaccine against a disease associated with PCV2 and PRRSV infection.12 cl, 4 tbl, 4 ex
This research aimed to investigate the effect of PI3K (phosphatidylinositol 3-kinase)/AKT (protein kinase B)/mTOR (mammalian target protein of rapamycin) signaling pathway-based clustering care combined with papaverine injection on vascular inflammation and vascular crisis after finger amputation and replantation. 100 patients admitted in General Hospital of Ningxia Medical University from April 2022 to December 2022 for replantation of severed fingers were selected and divided into a control group (n = 50) and an observation group (n = 50) using the randomized grouping principle. The control group received a papaverine injection and general nursing care, the observation group received a papaverine injection and clustered care. The pain score; constipation incidence; replantation finger survival rate; physician, nurse, and patient satisfaction; serum inflammatory factors; vascular crisis parameters; and occurrence of adverse reactions were compared between the two patient groups. Enzyme-linked immunosorbent assay was performed to detect PI3K, AKT, and mTOR protein concentrations in the venous blood of the two groups, and statistical analysis of the data was performed. On postoperative day 7, the pain score and incidence of constipation in the observation group were lower than those in the control group (P < 0.05); the survival rate of reimplanted fingers in the observation group was 88.00%, which was higher than that in the control group 80.00% (P < 0.05); the satisfaction of doctors, nurses, and patients in the observation group was higher than that in the control group; the concentrations of interleukin-1 (IL-1), tumor necrosis factor (TNF-α), blood flow resistance index (RI), and arterial pulsatility index (PI) in the observation group were lower than those in the control group, while the concentration of interleukin-10 (IL-10), vascular diameter, and Vm (mean blood flow velocity) were higher in the observation group than those in the control group; the differences were statistically significant (P < 0.05). The difference in the incidence of adverse reactions between the two groups was not statistically significant (P > 0.05). The concentrations of PI3K, AKT, and mTOR proteins in the observation group were higher than those in the control group (P < 0.05). The concentrations of PI3K, AKT, and mTOR proteins in the observation group were higher than those in the control group (P < 0.05). Overall, these findings suggest that clustered care combined with papaverine injection reduces vascular inflammatory symptoms and vascular crisis in the treatment of severed finger replantation through the PI3K/AKT/mTOR signaling pathway.
KEY POINTS: CKD and high glucose–containing peritoneal dialysate alter peritoneal membrane contributing to peritoneal dialysis failure, with a poorly understood mechanism. CKD milieu activates the aryl hydrocarbon receptor pathway in the subperitoneal vasculature, increasing the peritoneal fibrosis and collagen deposition in humans and mice. An aryl hydrocarbon receptor inhibitor mitigates CKD and peritoneal dialysis–mediated peritoneal fibrosis, collagen deposition, and vasculogenesis in a mouse model.
BACKGROUND: CKD is a proinflammatory and profibrotic condition and can independently alter the peritoneal membrane structure. Peritoneal dialysis (PD) results in profound alterations in the peritoneal membrane. The mechanisms contributing to the alterations of the peritoneal membrane structure in CKD milieu, along with PD, are poorly understood.
METHODS: Here, we show that human CKD induces peritoneal membrane thickening, fibrosis, and collagen deposition and activates the aryl hydrocarbon receptor (AHR) pathway in the subperitoneal vasculature. Leveraging a novel model of PD in CKD mice, we confirm these CKD-induced changes in the peritoneal membrane, which are exacerbated on exposure to the peritoneal dialysate. Peritoneal dialysate further augmented the AHR activity in endothelial cells of peritoneal microvasculature in CKD mice.
RESULTS: Treatment of CKD mice with an AHR inhibitor in peritoneal dialysate for 2 weeks resulted in a seven-fold reduction in AHR expression in the endothelial cells of subperitoneal capillaries, a five-fold decrease in subperitoneal space, and a nine-fold decrease in fibrosis and collagen deposition compared with vehicle-treated CKD mice. AHR inhibition reduced inflammation, subperitoneal neovascular areas, and its downstream target, tissue factor. The AHR inhibitor treatment normalized the peritoneal dialysate-induced proinflammatory and profibrotic cytokines, such as IL-6, monocyte chemoattractant protein-1, and macrophage inflammatory protein 1 levels, in CKD mice.
CONCLUSIONS: This study uncovers the activation of the AHR-cytokine axis in the endothelial cells of subperitoneal vessels in humans and mice with CKD, which is likely to prime the peritoneal membrane to peritoneal dialysate–mediated alterations. This study supports further exploration of AHR as a potential therapeutic target to preserve the structural and functional integrity of the peritoneal membrane in PD.
218,295. Jena, E. June 26, 1923, [Convention date]. Void [Published under Sect. 91 of the Act]. Medicines for internal use; antitoxins and immunizing and like serums.-Medicinal substances of organic, inorganic, or bacterial origin are transformed into an active but harmless form by administering them, with the ordinary food or by injection, to a cow or other milk-producing animal so that thev appear in the milk in combination with the albumen, fat, or sugar. The milk may be used as such or may be dried, condensed, or used in the preparation of milk chocolate, or treated to separate, the active substance. In the case of alkaloids, toxins, and bacterial products, these are administered to the animal after a preliminary treatment with other medical substances stated to impart an unspecific immunity. Numerous substances or combinations of substances which may be employed are mentioned in the Specification. Examples of such specified substances are colloidal silicic acid, wax, caoutchouc, halogen compounds, arsenic compounds, ichtyol, mercury compounds, iron compounds, alkaloids, diphtheria toxin and preparations of tubercle bacilli.
Revision total hip arthroplasty (THA) is a procedure with many challenges, especially when patients exhibit femoral bone defects. The causes of these defects vary, ranging from removal of prior implants to aseptic loosening. As surgeons navigate these challenges, a reliable surgical system is important. One modular fluted tapered system provides surgeons with tools to address complex hip revision cases. Introduced in 2003, this system has been utilized in over 180,000 procedures, demonstrating its reliability and effectiveness. Previously, the body stem came in sizes 155mm to 235mm. In the discussed case series, we present six distinct patient cases that highlight the advantages and efficacy of a newly introduced modification of the system; that is the use of smaller stemmed components (now 115mm). With each patient presenting unique challenges, we have demonstrated the use of this new short-stem version for multiple applications for various revision scenarios.
FIELD: medicine, oncology. SUBSTANCE: mammary tumor cells were treated by light and specific inhibitor of enzymatic conversion of protoporphyrinogen to protoporphyrin-IX catalyzed by protoporphyrin oxidase in the presence of porphyrin. Method involves the use of pharmaceutical composition containing specific inhibitor of enzymatic conversion of protoporphyrinogen to protoporphyrin-IX catalyzed by protoporphyrin oxidase. Index I 50  for protoporphyrin oxidase is less 1 mcM and negative reductive-oxidizing potential is above -500 mV. EFFECT: improved method of tumor cells destruction. 11 cl, 5 tbl, 1 dwg
86 patients with an episode of major depression associated with bipolar disorder, type I will be recruited by two sites for the study over fifteen months. Medication will be administered in a double-blind manner. Patients will receive asenapine (or placebo) beginning on day 0 at 5 mg bid. Dose may be increased to 10 mg bid and adjusted based on clinical response. Patients will be evaluated by a blinded (to treatment status) rater. Patients will be seen and ratings obtained at baseline (day 0) and on days 7, 14, 28, 42, and 56 (or termination from the study). Adverse events will be evaluated as well.
The study will consist of Phase Ib and Phase II. The study is planning to recruit approximately 152 patients in total for advanced/metastatic GI cancers, which include 24 patients in Phase Ib and up to approximately 128 patients in Phase II. For GC, HCC, and BTC groups, up to approximately 24 patients may be enrolled in Phase Ib and Phase II. For CRC group, up to approximately 80 patients may be enrolled in Phase Ib and Phase II with up to 40 patients in each subgroup.
FIELD: medicinal genetics. SUBSTANCE: APJ-receptor consisting of seven transmembranous domains could operate as coreceptor at infecting cells with HIV. The first object of the present innovation is the line of human cells transformed with APJ polypeptide-coding polynucleotide and/or CD4 polypeptide-coding polynucleotide, moreover, it simultaneously expresses APJ and CD4 polypeptides. The present innovation, also, refers to antibody specifically bound with extracellular APJ domain and inhibits HIV infection of target cell that simultaneously expresses APJ and CD4 polypeptides, or inhibits membranous fusion between the first cell simultaneously expressing APJ and CD4 and the second one expressing HIV env-protein. Another object of investigation is, also, practically purified APJ peptide fragment that inhibits HIV infection of target cell simultaneously expressing APJ and CD4 polypeptides, or inhibits membranous fusion between the first cell simultaneously expressing APJ and CD4 and the second one expressing HIV env-protein. Moreover, the present innovation deals with the methods to detect compounds that modulate interaction between HIV and APJ-receptor, method for inhibiting HIV infection of target cell expressing APJ and CD4 polypeptides due to the contact of target cell with efficient quantity of agent either binding or blocking APJ and, also, method for inhibiting HIV infection or that of relative disease by introducing therapeutically efficient amount of antibody against APJ for patient. The present innovation enables to obtain increased number of preparations to control HIV infection. EFFECT: higher efficiency of modulation. 33 cl, 9 dwg, 3 ex, 1 tbl